Review: taking Effexor and Abilify together


Summary

Drug interactions are reported among people who take Effexor and Abilify together. This review analyzes the effectiveness and drug interactions between Effexor and Abilify. It is created by eHealthMe based on reports of 2,779 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Effexor

Effexor has active ingredients of venlafaxine hydrochloride. It is often used in depression. (latest outcomes from Effexor 69,032 users)

Abilify

Abilify has active ingredients of aripiprazole. It is often used in bipolar disorder. (latest outcomes from Abilify 51,149 users)

On Sep, 14, 2016

2,779 people who take Effexor, Abilify are studied.


Number of reports submitted per year:

Effexor and Abilify drug interactions.

Drug effectiveness over time:

Effexor:
  • < 1 month: 16.0% - (1 of 6 people)
  • 1 - 6 months: 16.0% - (2 of 12 people)
  • 6 - 12 months: 33.0% - (3 of 9 people)
  • 1 - 2 years: 50.0% - (5 of 10 people)
  • 2 - 5 years: 57.0% - (8 of 14 people)
  • 5 - 10 years: 23.0% - (4 of 17 people)
  • 10+ years: 72.0% - (8 of 11 people)
  • not specified: 0.0% - (0 of 0 people)
Abilify:
  • < 1 month: 16.0% - (3 of 18 people)
  • 1 - 6 months: 22.0% - (5 of 22 people)
  • 6 - 12 months: 66.0% - (4 of 6 people)
  • 1 - 2 years: 33.0% - (4 of 12 people)
  • 2 - 5 years: 75.0% - (3 of 4 people)
  • 5 - 10 years: 62.0% - (5 of 8 people)
  • 10+ years: 75.0% - (3 of 4 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Effexor:
  • female: 46.0% - (27 of 58 people)
  • male: 19.0% - (4 of 21 people)
Abilify:
  • female: 40.0% - (22 of 54 people)
  • male: 25.0% - (5 of 20 people)

Drug effectiveness by age:

Effexor:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 5 people)
  • 20-29: 58.0% - (7 of 12 people)
  • 30-39: 17.0% - (3 of 17 people)
  • 40-49: 28.0% - (7 of 25 people)
  • 50-59: 71.0% - (10 of 14 people)
  • 60+: 66.0% - (4 of 6 people)
Abilify:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 4 people)
  • 20-29: 30.0% - (4 of 13 people)
  • 30-39: 25.0% - (4 of 16 people)
  • 40-49: 36.0% - (8 of 22 people)
  • 50-59: 69.0% - (9 of 13 people)
  • 60+: 33.0% - (2 of 6 people)

Most common drug interactions over time *:

< 1 month:
  • suicide attempt
  • restlessness
  • insomnia
  • leukopenia
  • agitation
  • weight increased
  • tachycardia
  • anxiety
  • blood prolactin increased
  • confusional state
1 - 6 months:
  • type 2 diabetes mellitus
  • depression
  • obesity
  • suicidal ideation
  • hyperglycaemia
  • vomiting
  • diabetic neuropathy
  • neuropathy peripheral
  • diabetes mellitus
  • hypoglycaemia
6 - 12 months:
  • suicidal ideation
  • foetal exposure during pregnancy
  • tremor
  • anxiety
  • bronchopulmonary dysplasia
  • drug ineffective
  • foetal growth restriction
  • hyponatraemia
  • inappropriate antidiuretic hormone secretion
  • neonatal intestinal obstruction
1 - 2 years:
  • diabetes mellitus
  • somnolence
  • type 2 diabetes mellitus
  • bite
  • compulsions
  • hyperglycaemia
  • psychomotor hyperactivity
  • thirst
  • dyskinesia
  • cardiopulmonary failure
2 - 5 years:
  • diabetes mellitus
  • abdominal pain
  • cough
  • oedema peripheral
  • type 2 diabetes mellitus
  • deep vein thrombosis
  • pulmonary embolism
  • asthenia
  • contusion
  • drug withdrawal syndrome
5 - 10 years:
  • weight increased
  • urinary incontinence
  • suicidal ideation
  • convulsion
  • hallucination
  • type 2 diabetes mellitus
  • anxiety
  • blood cholesterol increased
  • blood creatine phosphokinase increased
  • blood triglycerides increased
10+ years:
  • movement disorder
  • type 2 diabetes mellitus
  • apathy
  • coronary artery disease
  • exhaustion, fatigue, lethargy, tiredness, weariness
  • multiple sclerosis
  • tachycardia
  • tardive dyskinesia
  • diabetes mellitus
  • fatigue
not specified:
  • diabetes mellitus
  • weight increased
  • type 2 diabetes mellitus
  • depression
  • anxiety
  • drug ineffective
  • suicidal ideation
  • nausea
  • blood cholesterol increased
  • dizziness

Most common drug interactions by gender *:

female:
  • type 2 diabetes mellitus
  • diabetes mellitus
  • weight increased
  • depression
  • anxiety
  • nausea
  • suicidal ideation
  • insomnia
  • drug ineffective
  • blood cholesterol increased
male:
  • weight increased
  • diabetes mellitus
  • type 2 diabetes mellitus
  • depression
  • drug ineffective
  • dizziness
  • somnolence
  • metabolic syndrome
  • suicidal ideation
  • suicide attempt

Most common drug interactions by age *:

0-1:
  • diabetes mellitus
  • foetal exposure during pregnancy
  • blood cholesterol increased
  • blood triglycerides increased
  • bronchopulmonary dysplasia
  • foetal growth restriction
  • neonatal intestinal obstruction
  • premature baby
  • agitation neonatal
  • anal abscess
10-19:
  • rhabdomyolysis
  • renal failure acute
  • psychomotor hyperactivity
  • somnolence
  • suicide attempt
  • thirst
  • dystonia
  • serotonin syndrome
  • suicidal ideation
  • vomiting
20-29:
  • weight increased
  • suicide attempt
  • type 2 diabetes mellitus
  • insomnia
  • anxiety
  • depression
  • diabetes mellitus
  • hyperhidrosis
  • drug ineffective
  • leukopenia
30-39:
  • diabetes mellitus
  • type 2 diabetes mellitus
  • weight increased
  • blood cholesterol increased
  • anxiety
  • blood triglycerides increased
  • depression
  • obesity
  • pain
  • suicidal ideation
40-49:
  • diabetes mellitus
  • type 2 diabetes mellitus
  • weight increased
  • obesity
  • hypothyroidism
  • liver function test abnormal
  • metabolic syndrome
  • neuropathy peripheral
  • diabetic neuropathy
  • depression
50-59:
  • type 2 diabetes mellitus
  • depression
  • diabetes mellitus
  • weight increased
  • dizziness
  • anxiety
  • suicidal ideation
  • insomnia
  • nausea
  • drug ineffective
60+:
  • depression
  • drug ineffective
  • fall
  • fatigue
  • insomnia
  • nausea
  • tardive dyskinesia
  • weight increased
  • diabetes mellitus
  • pancreatitis

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Effexor and Abilify?

Can you answer these questions?

More questions for: Effexor, Abilify

You may be interested in these reviews

More reviews for: Effexor, Abilify

On eHealthMe, Effexor (venlafaxine hydrochloride) is often used to treat depression. Abilify (aripiprazole) is often used to treat bipolar disorder. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.